Observe Medical

Celluminova specializes in the development of new tools for stem cell research, including cancer stem cells.

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses.

ChemoTech is a Scandinavian company based at Medicon Village in Lund, Sweden. The company’s founders have extensive experience of cancer treatment through surgical oncology and clinical development. The company is dedicated to using its unique patented know-how to develop innovation in cancer care through genuine research and clinical trials.

Spermosens is a medical equipment manufacturer that produces technologies for diagnosing male-factor infertility.

IRLAB is a Swedish drug discovery and development company providing novel treatments for disorders of the brain. IRLAB is engaged in programmes targeting core dysfunctions in Parkinson’s disease and dementias. IRLAB has identified, and is currently engaged in clinical development of, two novel compounds aimed at offering improved clinical benefit for patients with Parkinson’s disease.

The AlzeCure Foundation is focused on the development of novel diagnostics and therapeutics for PD, AD and related neurodegenerative disorders. Conceptually, AlzeCure is an industry-standard incubator for novel projects. It comprises key professionals exhibiting complementary expertise from molecule to man.

Blodtrycksdoktorn is an evidence-based digital innovation that uses telemedicine, mobile health technology, and home blood pressure monitoring (HBPM) to provide a novel approach to managing hypertension.

B! BB Instruments develops an instrument that allows quick and easy sampling of suspected cancer tumors by drilling into the tissue. This makes it possible to reach deep-lying tumors. This differs from today's methods that are difficult to capture deeply lying tissue.

Beactica Therapeutics AB is a precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics to treat genetically defined cancers with significant unmet clinical need. Beactica’s approach is centered around targeting disease proteins with synthetic lethality vulnerabilities by applying its molecular interaction-based drug discovery engine to generate novel small molecule across synergistic modalities, including allosteric modulators and targeted protein degraders (PROTACs). Beactica deliver value to patients and shareholders by advancing its programmes into early clinical trials.

Loovi is a health technology firm that provides a doctor-led, data-driven longevity solution. It focuses on preventive health by using biomarker testing and tailored coaching.

Yazen is a digital healthcare provider that offers tailored weight loss programs, combining medical treatments with lifestyle coaching. The platform connects users with a team of experts, including doctors, dietitians, and personal trainers, to create individualized weight management plans.

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.